Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

Udovicich, Cristian; Callahan, Jason; Bressel, Mathias; Ong, Wee Loon; Perera, Marlon; Azad, Arun; Haran, Shankar; Moon, Daniel; Chander, Sarat; Shaw, Margaret; Eapen, Renu; Goad, Jeremy; Lawrentschuk, Nathan; Murphy, Declan; Hofman, Michael S

doi:10.1016/j.euros.2022.08.001

Cited by 23 publications

(27 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While a comprehensive review of 93 studies revealed the diagnostic value of radiomics in the differentiation of RCC [29], another systematic review including 331 patients concluded that PSMA-targeted PET/CT imaging was associated with enhanced detection in ccRCC and could be utilized as a biomarker of disease aggressiveness [30]. Additionally, a retro-spective study of 61 patients who underwent PSMA PET/CT for restaging or suspected metastatic RCC demonstrated PSMA PET-positive disease in 84% of patients, resulting in a change in management in 49% of patients [31].…”

Section: Discussionmentioning

confidence: 99%

Characterization of FOLH1 Expression in Renal Cell Carcinoma

Ovruchesky,

Pan,

Guer

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Purpose: Given the emergence of PSMA-targeted diagnostic agents and therapeutics, we sought to investigate patterns of FOLH1 expression in RCC and their impacts on RCC outcomes. Methods: We conducted a pooled multi-institutional analysis of patients with RCC having undergone DNA and RNA next-generation sequencing. FOLH1-high/low expression was defined as the ≥75th/<25th percentile of RNA transcripts per million (TPM). Angiogenic, T-effector, and myeloid expression signatures were calculated using previously defined gene sets. Kaplan–Meier estimates were calculated from the time of tissue collection or therapy start. Results: We included 1,724 patients in the analysis. FOLH1 expression was significantly higher in clear cell (71%) compared to non-clear cell RCC tumors (19.0 versus 3.3 TPM, p < 0.001) and varied by specimen site (45% primary kidney/55% metastasis, 13.6 versus 9.9 TPM, p < 0.001). FOLH1 expression was correlated with angiogenic gene expression (Spearman = 0.76, p < 0.001) and endothelial cell abundance (Spearman = 0.76, p < 0.001). While OS was similar in patients with FOLH1-high versus -low ccRCC, patients with FOLH1-high clear cell tumors experienced a longer time on cabozantinib treatment (9.7 versus 4.6 months, respectively, HR 0.57, 95% CI 0.35–0.93, p < 0.05). Conclusions: We observed differential patterns of FOLH1 expression based on histology and tumor site in RCC. FOLH1 was correlated with angiogenic gene expression, increased OS, and a longer duration of cabozantinib treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of FOLH1 Expression in Renal Cell Carcinoma

Ovruchesky,

Pan,

Guer

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are several small, prospective pilot studies that demonstrate increased sensitivity of PSMA-PET compared to conventional imaging in the staging and restaging of RCC (7)(8)(9). In a retrospective case series from Australia comparing PSMA-PET and conventional imaging, management was changed in approximately half of patients as a direct result of PSMA-PET findings when compared to conventional imaging (10).…”

Section: Discussionmentioning

confidence: 99%

Detection of Testicular Metastasis from Renal Cell Carcinoma on PSMA-PET Scan

Olmstead,

Emmerling,

Bantumilli

et al. 2024

jkcvhl

View full text Add to dashboard Cite

The use of prostate-specific membrane antigen–positron emission tomography (PSMA-PET) is becoming more widespread for the diagnosis and management of prostate cancer. Here we report a case of oligometastatic renal cell carcinoma (RCC) to the testes diagnosed incidentally on PSMA-PET imaging. This case demonstrates the potential for diagnosis of nonprostate disease with PSMA-PET imaging, as well as the promising nature of PSMA-PET for the diagnosis and surveillance of RCC. In addition, this case report discusses the rare occurrence of oligo-metastatic RCC to the testis.

show abstract

“…Other centres have reported higher impacts, such as Udovicich and colleagues who reported management change for 49% [ 14 ]. Their cohort had a higher proportion of oligometastatic disease considered for local therapies based on conventional imaging compared to the current cohort (72% vs 33%, respectively), where management is more likely to change according to the current dataset (44%).…”

Section: Discussionmentioning

confidence: 99%

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Pathmanathan,

Tariq,

Pearce

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC). Methods A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment. Results

show abstract

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma

Cited by 23 publications

References 36 publications

Characterization of FOLH1 Expression in Renal Cell Carcinoma

Characterization of FOLH1 Expression in Renal Cell Carcinoma

Detection of Testicular Metastasis from Renal Cell Carcinoma on PSMA-PET Scan

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Contact Info

Product

Resources

About